Amneal Pharmaceuticals, Inc.
AMRX· Nasdaq
AMRXAmneal Pharmaceuticals, Inc.
Quarterly figures for Amneal Pharmaceuticals, Inc., with source filings when available.
38 quarters. Mar 31, 2017 to Jun 30, 2026. USD.
Amneal Pharmaceuticals, Inc. has filed its 10-Q within 37 to 43 days of period end across its last 8 quarters. The 10-K runs 58 to 74 days.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Source trail |
|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | |||||||||
| Q2 2026 | Jun 30, 2026 | Jul 30, 2026 · pre-market | Aug 6, 2026 | 37 d | 10-Q | $796.20M | +9.9% | $0.18 | |
| Q1 2026 |
|---|
| Mar 31, 2026 |
| May 7, 2026 · after-hours |
| May 7, 2026 |
| 37 d |
| 10-Q |
| $722.52M |
| +3.9% |
| $0.19 |
| FY 2025 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2025derived | Dec 31, 2025 | Jan 13, 2026 · pre-market | Feb 27, 2026 | 58 d | 10-K | $814.32M | +11.5% | — | |
| Q3 2025 | Sep 30, 2025 | Oct 30, 2025 · pre-market | Nov 6, 2025 | 37 d | 10-Q | $784.51M | +11.7% | $0.01 | |
| Q2 2025 | Jun 30, 2025 | Aug 5, 2025 · pre-market | Aug 7, 2025 | 38 d | 10-Q | $724.51M | +3.2% | $0.07 | |
| Q1 2025 | Mar 31, 2025 | May 2, 2025 · pre-market | May 7, 2025 | 37 d | 10-Q | $695.42M | +5.5% | $0.04 | |
| FY 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2024derived | Dec 31, 2024 | Jan 15, 2025 · pre-market | Feb 28, 2025 | 59 d | 10-K | $730.52M | +18.4% | — | |
| Q3 2024 | Sep 30, 2024 | Nov 12, 2024 · after-hours | Nov 12, 2024 | 43 d | 10-Q | $702.47M | +13.3% | $0.00 | |
| Q2 2024 | Jun 30, 2024 | Aug 9, 2024 · pre-market | Aug 9, 2024 | 40 d | 10-Q | $701.78M | +17.1% | $0.02 | |
| Q1 2024 | Mar 31, 2024 | May 3, 2024 · pre-market | May 8, 2024 | 38 d | 10-Q | $659.19M | +18.2% | -$0.30 | |
| FY 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2023derived | Dec 31, 2023 | Jan 10, 2024 · pre-market | Mar 14, 2024 | 74 d | 10-K | $616.98M | +1.2% | — | |
| Q3 2023 | Sep 30, 2023 | Nov 7, 2023 · pre-market | Nov 9, 2023 | 40 d | 10-Q | $620.04M | +13.7% | $0.06 | |
| Q2 2023 | Jun 30, 2023 | Aug 4, 2023 · pre-market | Aug 8, 2023 | 39 d | 10-Q | $599.05M | +7.1% | $0.08 | |
| Q1 2023 | Mar 31, 2023 | May 5, 2023 · pre-market | May 9, 2023 | 39 d | 10-Q | $557.54M | +12.0% | -$0.05 | |
| FY 2022 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2022derived | Dec 31, 2022 | Jan 10, 2023 · pre-market | Mar 3, 2023 | 62 d | 10-K | $609.76M | +13.6% | — | |
| Q3 2022 | Sep 30, 2022 | Nov 4, 2022 · pre-market | Nov 7, 2022 | 38 d | 10-Q | $545.56M | +3.2% | -$0.02 | |
| Q2 2022 | Jun 30, 2022 | Aug 5, 2022 · pre-market | Aug 8, 2022 | 39 d | 10-Q | $559.36M | +4.5% | -$0.80 | |
| Q1 2022 | Mar 31, 2022 | May 4, 2022 · pre-market | May 6, 2022 | 36 d | 10-Q | $497.63M | +0.9% | -$0.01 | |
| FY 2021 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2021derived | Dec 31, 2021 | Jan 11, 2022 · pre-market | Mar 1, 2022 | 60 d | 10-K | $536.90M | +5.3% | — | |
| Q3 2021 | Sep 30, 2021 | Nov 3, 2021 · pre-market | Nov 8, 2021 | 39 d | 10-Q | $528.59M | +1.8% | -$0.03 | |
| Q2 2021 | Jun 30, 2021 | Aug 9, 2021 · pre-market | Aug 9, 2021 | 40 d | 10-Q | $535.08M | +15.2% | $0.10 | |
| Q1 2021 | Mar 31, 2021 | May 7, 2021 · pre-market | May 7, 2021 | 37 d | 10-Q | $493.11M | −1.1% | $0.04 | |
| FY 2020 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2020derived | Dec 31, 2020 | Feb 26, 2021 · pre-market | Mar 1, 2021 | 60 d | 10-K | $510.03M | +28.4% | — | |
| Q3 2020 | Sep 30, 2020 | Nov 6, 2020 · pre-market | Nov 6, 2020 | 37 d | 10-Q | $519.29M | +37.3% | -$0.06 | |
| Q2 2020 | Jun 30, 2020 | Aug 6, 2020 · pre-market | Aug 6, 2020 | 37 d | 10-Q | $464.66M | +14.8% | -$0.08 | |
| Q1 2020 | Mar 31, 2020 | May 11, 2020 · pre-market | May 11, 2020 | 41 d | 10-Q | $498.53M | +11.7% | $0.78 | |
| FY 2019 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2019 | Dec 31, 2019 | Feb 26, 2020 · pre-market | Mar 2, 2020 | 62 d | 10-K | $397.33M | −20.1% | -$0.23 | |
| Q3 2019 | Sep 30, 2019 | Nov 6, 2019 · pre-market | Nov 7, 2019 | 38 d | 10-Q | $378.28M | −20.6% | -$2.03 | |
| Q2 2019 | Jun 30, 2019 | Aug 5, 2019 · pre-market | Aug 5, 2019 | 36 d | 10-Q | $404.64M | −2.2% | -$0.13 | |
| Q1 2019 | Mar 31, 2019 | — | May 9, 2019 | 39 d | 10-Q | $446.12M | +62.1% | -$0.37 | |
| FY 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2018 | Dec 31, 2018 | — | Mar 1, 2019 | 60 d | 10-K | $497.53M | +69.6% | -$0.07 | |
| Q3 2018 | Sep 30, 2018 | — | Nov 7, 2018 | 38 d | 10-Q | $476.49M | +87.1% | $0.05 | |
| Q2 2018 | Jun 30, 2018 | — | Aug 9, 2018 | 40 d | 10-Q | $413.79M | +59.2% | -$0.15 | |
| Q1 2018 | Mar 31, 2018 | — | May 15, 2018 | 45 d | 10-Q | $275.19M | +21.9% | $0.00 | |
| FY 2017 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2017 | Dec 31, 2017 | — | Mar 9, 2018 | 68 d | 10-K | $293.37M | — | $0.00 | |
| Q3 2017 | Sep 30, 2017 | — | — | — | — | $254.73M | — | $0.00 | |
| Q2 2017 | Jun 30, 2017 | — | — | — | — | $259.87M | — | $0.00 | |
| Q1 2017 | Mar 31, 2017 | — | — | — | — | $225.68M | — | $0.00 | |
